RESUMO
Previous studies of patients with myotonic dystrophy have demonstrated hyperinsulinism after glucose loading. This hyperinsulinism has been attributed by some investigators to tissue insulin resistance. We have directly studied insulin sensitivity of forearm muscle in patients having such hyperinsulinism. The effect of an intrabrachial arterial insulin infusion (100 mu U/kg per min) on glucose uptake was determined in six cases of myotonic dystrophy, six normal subjects, and in seven disease control subjects with myotonia or wasting from other disorders. There was no significant difference in insulin tolerance comparing myotonic dystrophy patients to the normal and disease control groups. Glucose tolerance and basal insulin levels were normal in the myotonic dystrophy patients, but hyperinsulinism occurred after glucose ingestion. After 25 min of intra-arterial insulin, the mean peak muscle glucose uptake in myotonic dystrophy was 2.54 +/- 0.54 mu mol/min per 100 ml forearm compared to 5.24 +/- 0.86 mu mol/min per 100 ml for disease controls (P is less than 0.05). Myotonic dystrophy patients showed a peak glucose uptake increment of only 2.6 +/- 0.2-fold over basal contrasted with the disease control value of 6.5 +/- 1.0-fold (P is less than 0.02) and the normal control value of 8.8 +/- 1.1-fold (P is less than 0.01). Thus, there was an absolute as well as a relative decrease in muscle insulin sensitivity in myotonic dystrophy patients compared to both control groups. The peak increments in arterio-superficial venous glucose concentration differences after insulin infusion were not significantly different comparing myotonic dystrophy and control groups. These data suggest that in myotonic dystrophy, there is insulin insensitivity of skeletal muscle.
Assuntos
Glicemia/metabolismo , Insulina/sangue , Músculos/metabolismo , Distrofia Miotônica/sangue , Adulto , Transporte Biológico/efeitos dos fármacos , Feminino , Antebraço/irrigação sanguínea , Glucose/metabolismo , Hormônio do Crescimento/sangue , Humanos , Insulina/farmacologia , Masculino , Pessoa de Meia-Idade , Distrofia Miotônica/metabolismo , Fluxo Sanguíneo Regional/efeitos dos fármacosRESUMO
Myotonic dystrophy is frequently associated with testicular atrophy. Since androgens may play a role in the maintenance of muscle mass, we have studied the levels of plasma testosterone and gonadotropins and of urinary 17-ketosteroids in 22 men with myotonic dystrophy, 36 normal men, and 16 men (control group) with muscle wasting. Results were correlated with muscle mass as estimated by creatinine excretion and total body potassium. Patients with myotonic dystrophy had significantly lower testosterone and higher gonadotropin levels than normal, and these changes were progressive in longitudinal studies. Testosterone levels were also lower than normal in disease control subjects. There was no correlation between low testosterone levels and diminished muscle mass in either myotonic dystrophy or disease control patients. The low plasma concentration of testosterone in men with myotonic dystrophy and other neuromuscular diseases does not appear to be directly related to their muscle wasting. This study does not exclude the possibility that an alteration in testosterone receptor or tissue effects may contribute to a loss of muscle tissue.
Assuntos
Distrofia Miotônica/metabolismo , 17-Cetosteroides/sangue , 17-Cetosteroides/metabolismo , 17-Cetosteroides/urina , Adulto , Gonadotropina Coriônica/sangue , Gonadotropina Coriônica/metabolismo , Gonadotropina Coriônica/urina , Creatinina/metabolismo , Hormônio Foliculoestimulante/sangue , Hormônio Foliculoestimulante/metabolismo , Hormônio Foliculoestimulante/urina , Humanos , Hormônio Luteinizante/sangue , Hormônio Luteinizante/metabolismo , Hormônio Luteinizante/urina , Masculino , Pessoa de Meia-Idade , Distrofia Miotônica/sangue , Distrofia Miotônica/urina , Testosterona/sangue , Testosterona/metabolismo , Testosterona/urinaRESUMO
We performed sequential studies of two methods used to estimate muscle mass in 34 patients with progressive neuromuscular disease for periods of up to 52 months. Creatinine excretion and total body potassium were low at the outset in virtually all patients. Creatinine excretion continued to decline in most patients, but total body potassium did not decline significantly. Creatinine excretion may measure declining muscle mass more accurately than total body potassium, but both measurements can estimate muscle mass for metabolic studies or therapeutic trials.
Assuntos
Creatinina/metabolismo , Distrofias Musculares/metabolismo , Distrofia Miotônica/metabolismo , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Humanos , Masculino , Músculos/anatomia & histologia , Distrofias Musculares/patologia , Distrofia Miotônica/patologia , Potássio/metabolismoRESUMO
Muscle wasting in myotonic dystrophy appears to reflect impaired anabolism rather than accelerated catabolism. We therefore investigated the effects of testosterone, an anabolic hormone, on muscle mass as estimated by creatinine excretion and total body potassium in nine patients with myotonic dystrophy. Weekly injections of testosterone for 10 to 13 weeks increased both creatinine excretion (19%) and total body potassium (16%) in all patients. Metabolic balance data showed a confirmatory accretion of nitrogen, potassium, and phosphorus. Because testosterone increases indirect measures of muscle mass, it may deserve a therapeutic trial in myotonic dystrophy.
Assuntos
Creatinina/urina , Distrofia Miotônica/metabolismo , Potássio/análise , Testosterona/farmacologia , Adulto , Humanos , Pessoa de Meia-Idade , Músculos/efeitos dos fármacos , Testosterona/sangueRESUMO
Because testosterone has an anabolic effect in myotonic dystrophy, we conducted a 12-month, randomized, double-blind therapeutic trial of testosterone enanthate (3 mg/kg/wk) in 40 men with myotonic dystrophy. We evaluated strength by manual muscle tests, quantitative myometry, pulmonary function, and quantitative functional assessment. A sustained, significant elevation of testosterone levels was produced but there was no effect on any measurement of muscle strength. Muscle mass as estimated by creatinine excretion and lean body mass (40K method) increased significantly. We conclude that testosterone does not improve strength in myotonic dystrophy despite increasing muscle mass.
Assuntos
Distrofia Miotônica/tratamento farmacológico , Testosterona/análogos & derivados , Acne Vulgar/induzido quimicamente , Adolescente , Adulto , Idoso , Ensaios Clínicos como Assunto , Método Duplo-Cego , Humanos , Masculino , Pessoa de Meia-Idade , Músculos/fisiopatologia , Distrofia Miotônica/fisiopatologia , Distribuição Aleatória , Testosterona/efeitos adversos , Testosterona/uso terapêuticoRESUMO
We have studied the effect of a pharmacological dose of testosterone enanthate (3 mg.kg-1.wk-1 for 12 wk) on muscle mass and total-body potassium and on whole-body and muscle protein synthesis in normal male subjects. Muscle mass estimated by creatinine excretion increased in all nine subjects (20% mean increase, P less than 0.02); total body potassium mass estimated by 40K counting increased in all subjects (12% mean increase, P less than 0.0001). In four subjects, a primed continuous infusion protocol with L-[1-13C]leucine was used to determine whole-body leucine flux and oxidation. Whole-body protein synthesis was estimated from nonoxidative flux. Muscle protein synthesis rate was determined by measuring [13C]leucine incorporation into muscle samples obtained by needle biopsy. Testosterone increased muscle protein synthesis in all subjects (27% mean increase, P less than 0.05). Leucine oxidation decreased slightly (17% mean decrease, P less than 0.01), but whole-body protein synthesis did not change significantly. Muscle morphometry showed no significant increase in muscle fiber diameter. These studies suggest that testosterone increases muscle mass by increasing muscle protein synthesis.
Assuntos
Proteínas Musculares/biossíntese , Músculos/efeitos dos fármacos , Testosterona/farmacologia , Adulto , Peso Corporal , Creatinina/urina , Humanos , Leucina/metabolismo , Masculino , Músculos/anatomia & histologia , Músculos/metabolismo , Tamanho do Órgão/efeitos dos fármacos , Oxirredução , Potássio/metabolismo , Testosterona/sangueRESUMO
Fifty psychiatric inpatients with a prolonged length of stay were compared to 50 control admissions for factors associated with prolonged hospitalizations in a general hospital. Seven variables were found to be significantly overrepresented among the long stayers, including treatment with electroconvulsive therapy, medical consultations, underemployment, dementia, disposition to a place other than home, absence of alcohol or drug abuse, and presence of psychosis without affective symptoms. The clinical and policy implications of these finding are discussed.
Assuntos
Hospitais Gerais/economia , Tempo de Internação/economia , Transtornos Mentais/terapia , Unidade Hospitalar de Psiquiatria/economia , Controle de Custos , Transtorno Depressivo/terapia , Eletroconvulsoterapia , Emprego , Feminino , Hospitais Gerais/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Unidade Hospitalar de Psiquiatria/estatística & dados numéricos , Encaminhamento e ConsultaAssuntos
Exame Neurológico/métodos , Doenças Neuromusculares/diagnóstico , Biópsia/métodos , Estimulação Elétrica/métodos , Eletromiografia/métodos , Humanos , Doenças do Sistema Nervoso/patologia , Condução Nervosa , Doenças Neuromusculares/enfermagem , Doenças Neuromusculares/patologia , Educação de Pacientes como AssuntoRESUMO
For application of the Bodian method to frozen sections, cut frozen peripheral nerve or muscle at 10 mum and mount. Fix for 4 days in 18 parts 80% ethanol, 1 part 10% formalin, and 1 part glacial acetic acid. Fix central nervous tissue in the same mixture prior to freezing and sectioning, and after mounting postfix for 4 days. Impregnate by the Bodian procedure. The results equal Bodian stains of paraffin sections. The technique is simple and reliable. The use of 10 mum frozen sections produces little artifact and allows alternate serial sections to be stained with other techniques.
Assuntos
Secções Congeladas , Microtomia , Músculos/análise , Tecido Nervoso/análise , Coloração e Rotulagem , Animais , Córtex Cerebelar/análise , Cobaias , Humanos , Músculos/inervaçãoRESUMO
OBJECTIVE: --To study the changes in body composition produced by large doses of testosterone and reversal of changes when the drug is discontinued. DESIGN: --Weekly injections of testosterone enanthate were given to young adult male volunteers for 12 weeks. Repeated assays of lean body mass (LBM) by potassium 40 counting were made during this period and at intervals during the ensuing 5 to 6 months. PARTICIPANTS AND SETTING: --Subjects who were living on their own, who were known to be free of significant disease, and who volunteered as controls for a study of patients with neuromuscular disease. Assays were done in the Clinical Research Center. MAIN OUTCOME MEASURES: --Changes in body weight, LBM, and (by subtraction) body fat. RESULTS: --Testosterone treatment produced a progressive increase in LBM and a progressive decrease in body fat. Body composition reverted slowly toward normal when the injections were stopped; thus, the effects of testosterone lingered for some time. The magnitude of the observed changes in LBM was in keeping with the change in urinary creatinine excretion reported for these same subjects. CONCLUSION: --Testosterone is a powerful anabolic agent that also serves to reduce body fat content.
Assuntos
Composição Corporal/efeitos dos fármacos , Testosterona/análogos & derivados , Tecido Adiposo/química , Adulto , Índice de Massa Corporal , Humanos , Masculino , Testosterona/administração & dosagem , Testosterona/farmacologiaRESUMO
Myotonic dystrophy is associated with progressive muscular atrophy. In order to determine the mechanism of muscle wasting in this condition, we measured fractional mixed skeletal muscle protein synthesis in the postabsorptive state in 8 patients with myotonic dystrophy, and compared the results with those of 10 normal subjects. Fractional muscle protein synthesis was determined by measuring the increment of 13C leucine in mixed skeletal muscle protein obtained by needle biopsy from the quadriceps muscle during a primed-continuous infusion of L-(1-13C) leucine. We used plasma 13C alpha-ketoisocaproate (representing intracellular leucine labeling) as the precursor pool for the calculation of fractional muscle protein synthesis and leucine kinetics. Fractional muscle protein synthesis was depressed in the patients with myotonic dystrophy (28% decrease, p less than 0.02). Leucine flux, leucine oxidation, and the nonoxidative portion of leucine flux were not different between the patients with myotonic dystrophy and the normal control subjects. Muscle atrophy in myotonic dystrophy reflects a selective decrease in muscle protein synthesis without any similar decrease in nonmuscle protein synthesis. This decrease may result from an impaired end-organ response to anabolic hormones or substrates.